3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Recruiting
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Conditions
Pancreatic Neoplasms
3
Melanoma
2
Breast Neoplasms
2
Prostatic Neoplasms
1
Prostate Cancer Recurrent
1
Pancreatic Ductal Adenocarcinoma
1
Osteosarcoma
1
Neoplasm, Residual
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Interventions
Fulvestrant
63
Letrozole
53
Paclitaxel
49
Trastuzumab
41
pembrolizumab
40
ribociclib
37
Specimen Handling
37
palbociclib
36
Capecitabine
34
Carboplatin
33
Anastrozole
33
Tamoxifen
32
exemestane
29
pertuzumab
28
abemaciclib
28
Magnetic Resonance Spectroscopy
26
Cyclophosphamide
26
trastuzumab deruxtecan
24
Surveys and Questionnaires
21
Radiotherapy
18
Biopsy
18
olaparib
17
Standard of Care
16
Docetaxel
16
Blood Specimen Collection
16
Taxes
14
Mastectomy, Segmental
14
eribulin
13
elacestrant
13
130-nm albumin-bound paclitaxel
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Breast Neoplasms
×
Hydroxychloroquine
×
90 days
×
Clear all
NCT04523857
2026-05-26
ABBY
Abramson Cancer Center at Penn Medicine
Phase 2
Recruiting
44 enrolled
NCT04841148
2026-04-09
PALAVY
Abramson Cancer Center at Penn Medicine
Phase 2
Recruiting
96 enrolled